Previous 10 | Next 10 |
2024-01-22 19:45:34 ET Summary Catalyst Pharmaceuticals is a biopharmaceutical company specializing in treatments for rare neurological and epileptic disorders. The company's main products are Firdapse and Fycompa, which make up the majority of its revenue. The launch of Agamr...
2024-01-17 14:13:32 ET Summary Catalyst Pharmaceuticals, Inc. has one approved product and another about to be launched, but its market cap is low at $1.7bn. The company is facing a major patent challenge and has high expenses with no major data catalysts or pipeline molecules. ...
2024-01-16 10:50:09 ET Summary Investors are monitoring the S&P 500 stocks as the index starts the year with a pullback and uncertainty over interest rate cuts. Top-performing stocks include Juniper, Nvidia, Eli Lilly, Viatris, and Organon, while solar energy stocks and Boeing...
2024-01-12 12:54:48 ET Summary Viatris is an American pharmaceutical company formed as a result of the merger of Mylan and Upjohn. Over the past two and a half months, Viatris' share price has risen by more than 38%. Viatris' dividend yield is 3.97%, which is attractive becaus...
2024-01-09 12:34:10 ET Teva Pharmaceutical Industries Limited (TEVA) J.P. Morgan 42nd Annual Global Healthcare Conference January 08, 2024 11:15 AM ET Company Participants Richard Francis - President, CEO & Director Conference Call Participants Christophe...
2024-01-09 04:33:26 ET More on GSK GSK - Greenshoots In The Horizon Getting_Ahead_of_Respiratory_Diseases_Slides GSK, Teva, AstraZeneca under Senate probe over asthma inhaler pricing For further details see: GSK to buy Aiolos Bio for up to $1.4B to expand...
2024-01-08 15:45:47 ET More on AstraZeneca, GSK, etc. Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AbbVie Vs. GSK: Dual Dominance In Pharma GSK - Greenshoots In The Horizon FDA evaluating reports of GLP-1 drugs and negative side effects ...
2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...
2024-01-06 09:22:48 ET Summary Johnson & Johnson is a Dividend King focused on the creation and manufacturing of medical devices, vaccines, and medicines. Sales of Darzalex, an anti-CD38 monoclonal antibody, were $2.5 billion in the third quarter of 2023, up 21.8% year-over-ye...
2024-01-03 12:41:17 ET More on Teva Pharmaceutical Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating) Teva Pharmaceutical Industries Limited (TEVA) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript) Teva: Deeply Undervalued FCF Machine ...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...